Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Acquired by French global healthcare giant Sanofi in 2011, Genzyme has made the security of its physical and intellectual assets a priority since the 1990s, and was among the first companies to define ...

Sanofi and Boehringer Ingelheim (BI), drug giants from Europe, have sought for local regulatory clearances from the Competition Commission of India (CCI), so that it can complete the global asset ...